Navigating hyperammonemic encephalopathy: Continuous renal replacement therapy in a urea cycle defect secondary to fibrolamellar hepatocellular carcinoma

  • Mudarres M
  • Griffin B
  • Azrieh B
  • et al.
N/ACitations
Citations of this article
1Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare liver cancer variant, accounting for less than 1% of primary hepatic malignancies, predominantly affecting young adults. This case report presents a 24-year-old patient with altered mental status, ultimately diagnosed with metastatic FL-HCC and secondary hyperammonemic encephalopathy, a rare but critical complication. Management involved continuous renal replacement therapy (CRRT), ammonia-scavenging agents, and targeted radiotherapy for the primary tumor. This report elucidates the clinical presentation of FL-HCC, explores the pathophysiology of hyperammonemia-induced encephalopathy, and discusses management strategies, emphasizing the therapeutic role of dialysis modalities.

Cite

CITATION STYLE

APA

Mudarres, M. F., Griffin, B., Azrieh, B., Rose, A., Youssef, N., & Gopireddy, N. S. (2025). Navigating hyperammonemic encephalopathy: Continuous renal replacement therapy in a urea cycle defect secondary to fibrolamellar hepatocellular carcinoma. Journal of Onco-Nephrology, 9(2), 42–47. https://doi.org/10.1177/23993693251340194

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free